“The U.S. sales of drugs (Rx and OTC) in liquid form for oral administration exceeded $5.3 billion for the year 2013” – Flamel’s Proprietary Drug Delivery Platform. July 2014: 14
The truth can be a bitter pill to swallow. More literally, the truth for many people is that bitter pills are hard to swallow. That’s why there is a need for microparticle liquid suspensions for people who have difficulty swallowing oral tablets and capsules.
Many people have trouble swallowing some forms of oral medication. In 2013, a study was conducted to further examine this condition. Of the 1,051 patients who participated in the study, 37.4% experienced difficulty while attempting to swallow tablets and capsules, and 9% frequently had trouble. This problem is exacerbated in pediatric and geriatric populations. Difficulty swallowing impacts 15 million Americans of all ages, and 60,000 Americans die each year from complications associated with swallowing dysfunctions.
For those who live, the lack of available oral liquid suspensions can lead to noncompliance. According to a 2003 study conducted by Harris Interactive, 14% of patients who had trouble swallowing tablets and capsules delayed taking their medication, 8% skipped a dose and 4% stopped taking the medication altogether. Difficulty swallowing tablets and capsules has a direct effect on compliance. Sustained-release, extended-release and pulse-release tablets and capsules must be swallowed whole. Cutting, grinding and chewing them will hinder the drug delivery process and are forms of noncompliance.
There is an immense need for liquid suspensions for people who have trouble swallowing oral tablets and capsules. Orbis Biosciences uses OptimµmTM technology to create uniform microparticles that can be used in liquid suspensions. As such technology continues to grow and liquid medications become more available, the phrase “a bitter pill to swallow” will become just that – a phrase.